Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
Laura C CoatesPhillip J MeaseDafna D GladmanSandra NavarraWeibin BaoCorine GaillezPublished in: RMD open (2023)
Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.